• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.

    5/19/26 4:03:41 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)


    Nkarta, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    65487U108

    (CUSIP Number)
    Stephanie Brecher
    New Enterprise Associates, 1954 Greenspring Drive, Suite 600
    Timonium, MD, 21093
    (410)842-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/19/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    New Enterprise Associates 15, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    NEA Partners 15, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    NEA 15 GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    Forest Baskett
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    Anthony A. Florence, Jr.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    Mohamad H. Makhzoumi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    65487U108


    1 Name of reporting person

    Scott D. Sandell
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,568,781.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,568,781.00
    11Aggregate amount beneficially owned by each reporting person

    3,568,781.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.9 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    Nkarta, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    1150 Veterans Boulevard, South San Francisco, CALIFORNIA , 94080.
    Item 1 Comment:
    This Amendment No. 3 ("Amendment No. 3") to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on July 23, 2020 (the "Schedule 13D"), Amendment No. 1 thereto filed on May 5, 2022 ("Amendment No. 1"), and Amendment No. 2 thereto filed on March 28, 2024 ("Amendment No. 2") relating to the Common Stock of the Issuer. Certain terms used but defined in this Amendment No. 3 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). This Amendment No. 3 is being filed to reflect the exit from reporting status by the Reporting Persons (as defined below) as a result of an increase in the number of Common Stock outstanding.
    Item 2.Identity and Background
    (a)
    New Enterprise Associates 15, L.P. ("NEA 15"); NEA Partners 15, L.P. ("NEA Partners 15"), which is the sole general partner of NEA 15; NEA 15 GP, LLC ("NEA 15 LLC," and together with NEA Partners 15, the "Control Entities") which is the sole general partner of NEA Partners 15; Forest Baskett ("Baskett"), Anthony A. Florence, Jr. ("Florence"), Mohamad H. Makhzoumi ("Makhzoumi"), and Scott D. Sandell ("Sandell") (together, the "Managers"). The Managers are the managers of NEA 15 LLC. The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)
    The address of the principal business office of each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.
    (c)
    The principal business of NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities and a number of affiliated partnerships with similar businesses.
    (d)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    NEA 15 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Not applicable.
    Item 4.Purpose of Transaction
     
    NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.
    Item 5.Interest in Securities of the Issuer
    (a)
    NEA 15 is the record owner of the NEA 15 Shares. As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares. Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares other than those shares which such person owns of record. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 71,545,358 shares of Common Stock reported by the Issuer to be outstanding as of May 7, 2026 on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.
    (b)
    Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
    (c)
    None of the Reporting Persons have effected any transaction in the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.
    (e)
    Each of the Reporting Persons has ceased to beneficially own five percent (5%) or more of the Issuer's Common Stock as of May 12, 2026.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    New Enterprise Associates 15, L.P.
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    NEA Partners 15, L.P.
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    NEA 15 GP, LLC
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:05/19/2026
     
    Forest Baskett
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Forest Baskett
    Date:05/19/2026
     
    Anthony A. Florence, Jr.
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Anthony A. Florence Jr.
    Date:05/19/2026
     
    Mohamad H. Makhzoumi
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Mohamad H. Makhzoumi
    Date:05/19/2026
     
    Scott D. Sandell
     
    Signature:/s/ Nicole Hatcher
    Name/Title:Nicole Hatcher as attorney-in-fact for Scott D. Sandell
    Date:05/19/2026
    Comments accompanying signature:
    This Amendment No. 3 to Schedule 13D was executed by Nicole Hatcher on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
    Get the next $NKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Mkt Perform
    William Blair
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    More analyst ratings

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $13 Million Company Teaching the Immune System to Hunt Cancer

    Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep

    5/29/26 9:00:00 AM ET
    $ARTV
    $FATE
    $GTBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

    Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol

    5/19/26 9:00:00 AM ET
    $FATE
    $GTBP
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

    Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026Cash balance of $266.7 million on March 31, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di

    5/12/26 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.

    SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)

    5/19/26 4:03:41 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nkarta Inc.

    10-Q - Nkarta, Inc. (0001787400) (Filer)

    5/12/26 4:09:54 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nkarta, Inc. (0001787400) (Filer)

    5/12/26 4:04:35 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nkarta downgraded by William Blair

    William Blair downgraded Nkarta from Outperform to Mkt Perform

    5/15/25 8:09:11 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Nkarta with a new price target

    Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

    10/9/24 7:55:21 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta upgraded by Raymond James with a new price target

    Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

    8/14/24 7:45:34 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/29/24 5:38:04 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/28/24 4:30:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hastings Paul J sold $53,915 worth of shares (26,046 units at $2.07), decreasing direct ownership by 6% to 390,023 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:39:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Mahmood Nadir sold $11,693 worth of shares (5,649 units at $2.07), decreasing direct ownership by 3% to 167,727 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/20/26 5:38:03 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rose Shawn Marshall was granted 70,000 shares (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:50:36 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

    SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought

    6/6/25 8:52:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

    Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025

    5/14/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

    SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

    7/16/24 6:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Financials

    Live finance-specific insights

    View All

    Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

    New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

    10/17/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

    10/16/23 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

    6/27/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 4:05:12 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 8:55:31 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care